Research Articles | Page 5 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Family reflections: George Elliott: a first-person commentary on pediatric aplastic anemia research Aug 2024 Pediatric Research Aplastic Anemia
Consensus Recommendations for Severe Aplastic Anemia Aug 2024 Blood Advances Aplastic Anemia
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes Aug 2024 Journal of Clinical Oncology Myelodysplastic Syndromes (MDS)
Modified Delphi panel consensus recommendations for management of severe aplastic anemia Aug 2024 Blood Advances Aplastic Anemia
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Aug 2024 Haematologica Aplastic Anemia
Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan Jul 2024 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms Jul 2024 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors Jul 2024 PLOS One Paroxysmal Nocturnal Hemoglobinuria (PNH)
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes Jul 2024 Lancet Haematology Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Jul 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)